Genprex
GNPXGenprex is a clinical-stage biotechnology company developing gene-based therapies for large patient populations with significant unmet medical needs in oncology and diabetes.
Table of contents
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Genprex is a clinical-stage biotechnology company developing gene-based therapies for large patient populations with significant unmet medical needs in oncology and diabetes. The company's core value proposition centers on its proprietary ONCOPREX Delivery System, a non-viral, systemic platform that delivers tumor suppressor genes to cancer cells, and an AAV-based gene therapy approach for diabetes. Their lead programs aim to enhance the efficacy of existing targeted therapies and immunotherapies through multimodal mechanisms of action.
Genprex is a pioneer in systemic, non-viral gene therapy for cancer, holding exclusive worldwide licenses for key tumor suppressor genes and novel diabetes gene therapy technologies.
Questions, answered.
- What is Genprex's market cap?
- Genprex (GNPX) has a market capitalization of $3.9M and trades on NASDAQ.
- Who are Genprex's competitors?
- Genprex's key competitors include Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
- Who does Genprex partner with?
- Genprex's notable partners include The University of Texas MD Anderson Cancer Center, University of Pittsburgh, AstraZeneca, and others.
- What subsidiaries does Genprex have?
- Genprex's subsidiaries include Convergen Biotech, Inc..
- Where is Genprex headquartered?
- Genprex is headquartered in United States of America and employs approximately 25 people. It has been publicly traded since 2018.